Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

Inclusion Criteria:

- Subject has a clinical diagnosis of stable plaque psoriasis

Exclusion Criteria:

- Subject has spontaneously improving or rapidly deteriorating plaque psoriasis

- Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis

- Subject has used any phototherapy, photo-chemotherapy or systemic psoriasis therapy
within 30 days prior to initiation of treatment

- Subject has used systemic corticosteroids or topical, inhaled, intranasal
corticosteroids within 30 days and 14 days, respectively, prior to study screening

- Subject has had prolonged exposure to natural or artificial sources of ultraviolet
radiation within 30 days prior to initiation of treatment

- Subject has used topical psoriatic therapy including tar, anthralin, retinoids,
vitamin D analogs (e.g., Dovonex®) within 14 days prior to initiation of treatment

- Subject has used emollients/moisturizers on areas to be treated within one day prior
to initiation of treatment

- Subject is currently using lithium or Plaquenil (hydroxychloroquine)

- Subject is currently using a beta-blocking medication (e.g., propranolol) or
angiotensin converting enzyme (ACE) inhibitors (e.g., lisinopril) at a dose that has
not been stabilized

- Subject is pregnant, nursing or planning a pregnancy during the study period

- Subject is currently enrolled in an investigational drug, biologic or device study

- Subject has received an investigational drug, biologic or an investigational device
within 30 days prior to study start

- Subject has been previously enrolled in this study and treated with the test article

- Subject has an irregular sleep schedule or works night shifts